English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The title compound, C 15 H 21 N 3 O 3 S, is known to be an impurity of gliclazide [systematic name:  N -(hexa­hydro-1 H -cyclopenta[ c ]pyrrol-2-ylcarbamo­yl)-4-methyl­benzene­sulfonamide], a sul­fonyl­urea anti­diabetic drug. Gliclazide has a  p -tolyl group substituting the sulfonamide functionality, while the title mol­ecule contains an  o -tolyl group. Both five-membered fused rings adopt envelope conformations. In the crystal, N—H⋯O hydrogen bonds are formed between HN(C=O)NH groups, building centrosymmetric dimers. These dimers are further linked through N—H⋯O(sulfon­yl) contacts, forming chains in [100].

Gliclazide impurity F:N-[(perhydrocyclopenta[c]pyrrol-2-yl)aminocarbonyl]-o-toluenesulfonamide